Conclusion: In addition to inducing p75NTR up-regulation, inflammatory stimuli increase the release of proNGF in arthritis SFs. Autocrine proNGF binds to p75NTR and further enhances pro-inflammatory cytokine production, creating a vicious circle that amplifies the inflammatory response. Blocking the binding of endogenous proNGF to its receptor p75NTR strongly reduces the production of inflammatory mediators and prospects the use of p75NTR inhibitors as a new therapeutic approach to chronic arthritis.

REFERENCES
[1] Princiere, et al., Nerve Growth Factor Down regulates Inflammatory mediators and prospects the use of p75NTR inhibitors as a novel therapeutic approach to chronic arthritis. RMD Open. 2017

Disclosure of Interests: Luciapa Farina: None declared, Gaetana Minnone : None declared, Marzia Soligo : None declared, Luigi Manni : None declared, Gian Marco Moneta: None declared, Ivan Caiello: None declared, Luigi Manzo : None declared, Fabrizio De Benedetti Grant/research support from: Abbvie, SOBI, Novo- immunne, Roche, Novartis, Sanofi, Pfizer, Luisa Bracci-Laudiero: None declared

A SYSTEMS APPROACH TO INVESTIGATE INFLAMMATION RESOLUTION BY MULTICOMPONENT MEDICINAL PRODUCT TR14

Patrick Schopohl1, Suchi Smita1, F a i z K h a n1, Tom Gebhardt1, Matti Hoch1, Fabrizio De Benedetti Grant/research support from: Abbvie, SOBI, Novo-

None declared, Marzia Soligo : None declared, Luigi Manni : None declared, Gian Marco Moneta: None declared, Ivan Caiello: None declared, Luigi Manzo : None declared, Fabrizio De Benedetti Grant/research support from: Abbvie, SOBI, Novo-immune, Roche, Novartis, Sanofi, Pfizer, Luisa Bracci-Laudiero: None declared

BACKGROUND: Acute inflammation is a nonlinear, spatio-temporal process for the removal of invading pathogens and the repair of damaged tissues to re-establish homeostasis. If not resolved, it leads to chronic inflammatory clinical phenotypes. The current medical paradigm is based on using single-molecule inhibitors aiming to block certain molecular pathways involved in inflammation. Complex diseases, where large number of feedback mechanisms play a central role, require multi-target interventions [1].

OBJECTIVES: The objective of our study was to construct a comprehensive molecular interaction map (MIM) of acute inflammation and its resolution. We further aimed to understand the effect of Traumeel (TR14), a multipurpose drug, on inflammation resolution, by mapping previously published TR14 transcriptionomics data [2] from a wound healing murine model onto the MIM.

METHODS: We constructed a comprehensive MIM using damage-, and pathogen-associated molecular patterns (DAMPs and PAMPs) and established disease genes from selected acute inflammatory clinical phenotypes as seed molecules. From these seed molecules, we identified feedback loops (FBs) with the NetDS Cytoscape plugin using our previously published methodology [1]. All FBs were merged to create a core regulatory network responsible for the overall dynamics of acute inflammation initiation, transition and resolution.

Using TR14 transcriptionomics data to identify acute inflammatory processes enriched at various time points, we combined RPKM values of each individual splice variant into the parent gene using the RSEM method [3]. The expression profile of whole genes was favored due to the lack of splice variant-specific ontology data. Further, the fold change expression profile for each gene was calculated by comparing TR14-treated vs untreated mice. These data were mapped to the core regulatory network, and time point-specific sub-networks were identified by keeping nodes with absolute fold change expression of ≥ 1.5 and a p-value ≤ 0.05. Furthermore, we identified enriched immune-related processes regulated by TR14 at multiple time points using the Cytoscape ClueGo GO plugin.

RESULTS: The MIM has, as of January 2019, 3300 interactions, which are divided into 24 functional modules based on acute inflammation-related gene ontology terms. From the MIM, we identified 435 FBs which were merged to extract a core regulatory network. After mapping of TR14 gene expression fold change data at time points 12h, 24h, 36h, 72h, 96h, 120h and 192h, we identified that large numbers of FBs were differentially regulated at early time points. This number decreased substantially at later time points. At time point 192h, we could identify only 6 differentially regulated nodes with no specific role in immune regulation, indicating that the inflammation was resolved mostly before 192h after injury.

Conclusion: Molecular interaction maps facilitate gene expression data analysis to identify enriched molecular processes and cell/tissue specific-phenotypes. TR14-induced gene expression changes can be linked to inflammation-related biological functions as defined by enriched GO terms. Our analyses suggest that TR14 modulates multiple network components at early time points, which can be linked to inflammation resolution.

REFERENCES

Disclosure of Interests: Patrick Schopohl: None declared, Suchi Smita: None declared, Faiz Khan: None declared, Tom Gebhardt: None declared, Matt Hoch: None declared, David Brauer: None declared, Konstantin Csensleviclus Employee of: Biologische Heilmittel Heel GmbH, Myron Schultz Employee of: Biologische Heilmittel Heel GmbH, Olaf Wolkenhauer Grant/research support from: The project was financially supported by Biologische Heilmittel Heel GmbH (Heel), Consultant for: I have received consultancy honoraria from Heel, Shailendra Gupta Grant/research support from: The research project was financially supported by Biologische Heilmittel Heel GmbH (Heel), Consultant for: I have received consultancy honoraria from Heel


SERUM TENASCIN-C LEVELS ARE ELEVATED IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS

Hana Hulejová1, Kristyna Bubova2, Klára Prazdrojová3, Marketa Husaková2, Maria Filková1, Michal Tomčík1, Karei Pavelka2, Ladislav Šenolt2, 1Institute of Rheumatology, Prague, Czech Republic; 2Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

BACKGROUND: Tenascin-C (TNC) is a pro-inflammatory extracellular matrix glycoprotein that is synthesized in various pathological conditions. TNC induces inflammatory activity and promotes damage of joints. Its expression in adults is restricted to sites of tissue injury, particularly during phases of inflammation and active tissue remodelling. Only a few studies have described elevated serum TNC levels in ankylosing spondylitis (AS) compared to healthy controls (HC).

AIMS: The aim of this study was to examine the levels of serum TNC among different axial spondyloarthritides (axSpA) subsets and whether TNC levels are related to disease activity measures or other clinical features.

METHODS: Sixty-one patients who fulfilled the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA and twenty age and sex-matched HC included in this study. Based on imaging, patients were further classified as AS (n = 45) and as nr-axSpA (n = 16). Patients with AS were further divided into two subsets based on the absence (n = 22) or presence of syndesmophytes (n = 23). TNC serum levels were determined using ELISA. The following data were collected: clinical and laboratory disease activity measures; demographic status; disease-related factors such as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and CRP levels. Statistical analyses were performed with GraphPad Prism 5.1. The data are presented as the median and interquartile range.

RESULTS: TNC serum levels were elevated in axSpA patients (535.3 (457.7-677.2) ng/mL compared to HC (432.1 (329.1-565.9) ng/mL, p = 0.022). TNC serum levels did not correlate with disease activity biomarkers (serum CRP or BASDAI) in patients with axSpA. Although we have not observed correlation between TNC and mSASSS radiographic score, weak correlation with disease subsets was found (r = 0.25, p = 0.025).

CONCLUSION: We demonstrated here elevated serum TNC levels in patients with axSpA, particularly in those with syndesmophytes, which may suggest its role in bone formation during radiographic stage of the disease.

Acknowledgement: This work was supported by MH CR 023728, SVV 260373, AZV - 17-33127A

Disclosure of Interests: Hana Hulejova: None declared, Kristyna Bubova: None declared, Klára Prazdrojová: None declared, Marketa Husaková: None declared, Maria Filková: None declared, Michal Tomčík: None declared, Karei Pavelka: None declared, Ladislav Šenolt Grant/research support from: AbbVie, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene Corporation, Merck Sharp and Dohme, Novartis, Pfizer, Roche, UCB, Amgen, Takeda, Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Merck Sharp and Dohme, Novartis, Pfizer, Roche, UCB